Bally's Corporation has reported impressive financial results for the third quarter of 2026, showcasing a significant revenue increase that underscores the company's growth trajectory in the competitive hotels and motels sector.
On November 16, 2026, Bally's Corporation (NYSE: BALY) announced its financial performance for the quarter ending September 30, 2026. The results revealed a consolidated revenue of $807.6 million, marking a 21.7% increase compared to the same period last year. This growth reflects the company's strategic initiatives and operational enhancements.
Background
Bally's Corporation, incorporated in Delaware, operates within the hotels and motels sector (SIC: 7011). The company has undergone several name changes in recent years, previously known as Twin River Worldwide Holdings, Inc. Bally's is publicly traded on the New York Stock Exchange under the ticker symbol BALY.
What the Filing Says
The SEC filing details the results of operations and financial condition, noting, "Consolidated revenue of $807.6 million increased 21.7% year-over-year." The report highlights revenue growth across various segments, including casinos and resorts, which generated $408.6 million, up 3.2% year-over-year.
Impact
This strong financial performance may positively influence Bally's stakeholders, including investors and employees, as well as the broader industry, which is seeing a resurgence in consumer spending. The growth in revenue from the casinos and resorts segment indicates a robust recovery and potential for continued expansion in the hospitality sector.
What's Next
The filing does not say what happens next, but the company is likely to continue focusing on strategic growth initiatives and may provide further updates in future filings.
Read Next
DarkPulse, Inc. reports Q3 results in latest 10-Q filing
Vulcan Infrastructure & Power reports Q3 results
Parabolic Technologies reports Q3 results for 2026
Phunware Reports Q3 Results Amid Competitive Tech Landscape
Mesa Royalty Trust Reports Increased Royalty Income in Q3
AEON Biopharma reports third-quarter results for 2026







